Melanoma MedDRA version: 21.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864
Conditions
Interventions
Product Name: PEMBROLIZUMAB
Product Code: MK-3475
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Pembrolizumab
CAS Number: 1374853-91-4
Current Sponsor code: MK-3475
Concentration uni
Sponsors
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Has histologically or cytologically confirmed melanoma. 2. Has clinically detectable and resectable Stage IIIB or IIIC or IIID melanoma per AJCC 8th Edition Staging Criteria, with 1 or more macroscopic lymph node metastases that can be biopsied, and no current or history of in-transit metastases within the last 6 months. Melanoma must be amenable to surgery with curative intent. At baseline, patients may have a primary cutaneous melanoma lesion in addition to tumor-involved lymph node disease. “Resectable” is defined as lesion(s) without significant vascular, central nervous system or bony involvement as per the surgeon’s judgment, where tumor-free margins (R0) can safely be achieved with surgery. Participants with multiple regional tumor-involved lymph nodes are eligible. Participants with gross or microscopic extracapsular nodal extension are eligible. 3. Has the presence of at least 1 measurable lesion by CT or MRI per RECIST 1.1 (= 1.5 cm in short axis for a tumor-involved lymph node). 4. Has been untreated for Stage IIIB, IIIC or IIID melanoma except as follows: a. Surgical resection and re-resection of the primary melanoma is allowed. b. Prior radiotherapy to the primary melanoma, including after prior surgical resection, is allowed. c. No other prior anticancer therapy is allowed. 5. Has provided a baseline tumor biopsy. a. Participants must submit a tumor sample during Screening for confirmation of adequacy of tumor tissue at a central pathology laboratory. If participants have only 1 measurable lesion per RECIST 1.1, the biopsy specimen should be obtained from the nontarget lesion or archival tissue from the primary tumor. If biopsy specimen was obtained from a lone target lesion, a repeat screening CT must be obtained postbiopsy and measurable disease. Confirmation of presence of adequate tumor tissue by central pathology laboratory is required prior to randomization/allocation. b. The sites should submit tumor samples to the central pathology laboratory for assessment of the adequacy of tumor tissue and for biomarker analysis. 6. Is male or female from 18 years to 120 years at the time of signing the informed consent. 7. Has an ECOG performance status 0 to 1 (as assessed within 7 days of the first dose of study intervention). 8. Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during theintervention period and for at least 120 days, corresponding to time needed to eliminate study intervention(s) after the last dose of study intervention:Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) 9. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding,and at least one of the following conditions applies: Is not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective (with a failurerate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abst
Exclusion criteria
Exclusion criteria: 1. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention. Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. 2. Has a known additional malignancy that is progressing or requires active treatment within the past 2 years. Exceptions to the secondary malignancy exclusion include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, new nonulcerated primary melanoma <1 mm in depth with no nodal involvement, Grade 1 follicular lymphoma, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy. 3. Participants must not have any evidence of CNS metastasis and/or carcinomatous meningitis. 4. Has ocular or mucosal melanoma. 5. Has known hypersensitivity to active substances or any of their excipients including previous clinically significant hypersensitivity reaction to treatment with another mAb. 6. Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. 7. Has an active infection requiring systemic therapy. 8. Has known history of HIV (HIV 1/2 antibodies). No testing of HIV is required unless mandated by local health authority. 9. Has known history of hepatitis B (defined as HBsAg reactive) or known hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. 10. Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis. 11. Has a history of active tuberculosis (TB; Bacillus tuberculosis). 12. A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 13. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137, TIGIT). 14. Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to randomization/allocation. 15. Has received prior radiotherapy within 2 weeks of the first dose of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. 16. Has had major surgery (<3 weeks prior to the first dose of study intervention). 17. Has received a live vaccine within 30 days before the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. 18. Is currently participating in or has participated in a study of an investigational agent or has used an inv
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: 1.To assess the safety and tolerability of investigational treatment combinations based on the proportion of participants with adverse events (AEs) 2.To evaluate pathological complete response (pCR) rate as assessed by central review of the pathology results ;Secondary Objective: 1.To evaluate the near pathological complete response (near pCR) rate as assessed by central review of the pathology results 2.To evaluate pathological partial response (pPR) rate as assessed by central review of the pathology results 3.To evaluate recurrence-free survival (RFS) as assessed by the investigator ;Primary end point(s): 1. Percentage of participants who experience an adverse event (AE) 2. Percentage of participants who discontinue study treatment due to an AE 3. Pathological complete response (pCR) rate ;Timepoint(s) of evaluation of this end point: 1. Up to ~16 months 2. Up to ~12 months 3. Up to ~1.5 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Near pathological complete response (near pCR) rate 2. Pathological partial response (pPR) rate 3. Recurrence-free survival (RFS) ;Timepoint(s) of evaluation of this end point: 1. Up to ~1.5 months 2. Up to ~1.5 months 3. Up to ~65 months | — |
Countries
Australia, France, Germany, Israel, Italy, New Zealand, Switzerland, United States
Contacts
Public ContactGlobal Clinical Trial Operations
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Outcome results
None listed